Wegovy Tablet
Product Images NDC 0169-4409

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Wegovy (NDC 0169-4409). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novo Nordisk Pharmaceutical Industries, Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Table 1 (Image 01)

A data table displaying weight in pounds and kilograms along the top and height in inches and centimeters down the side, with cells containing numerical values representing a calculated metric, with certain cells highlighted in green. The table appears structured for reference based on height and weight ranges.*

FDA Label Image

Structural Formula (Image 02)

Chemical structure diagram of semaglutide, the active ingredient in the drug WEGOVY. The image depicts the molecular sequence and bonds of the peptide-based compound.*

FDA Label Image

Fig 2 (Image 03)

A horizontal dot plot showing relative exposure (Cavg) ratios with 90% confidence intervals for various intrinsic factors including sex (male), age groups (65-<75 years and >=75 years), race (Black or African American, Asian, American Indian or Alaska Native), ethnicity (Hispanic or Latino), body weight (74 kg and 143 kg), renal function (mild and moderate), and injection site (thigh and upper arm). The x-axis is logarithmic from 0.5 to 2.0, with a vertical line at 1.0 indicating the reference exposure level.*

FDA Label Image

Fig 3 (Image 04)

A forest plot chart showing the relative exposure ratio and 90% confidence interval for various co-administered medications including Metformin, S-warfarin, R-warfarin, Digoxin, Atorvastatin, Ethinylestradiol, and Levonorgestrel. The chart compares AUC and Cmax values, with ratios centered around 1, indicating no significant change in exposure levels.*

FDA Label Image

Fig 4 (Image 05)

A cumulative frequency graph comparing body weight change percentages between WEGOVY and placebo groups. The x-axis represents change in body weight (%) ranging from about -40% to +40%, and the y-axis shows cumulative frequency (%) from 0 to 100%. The graph includes two curves: one solid line labeled WEGOVY showing a higher body weight reduction than the dashed placebo line.*

FDA Label Image

Fig 5 (Image 06)

A cumulative frequency plot illustrating change in body weight percentage, comparing WEGOVY (semaglutide) and placebo groups. The x-axis represents percent change in body weight, ranging from about -40% to +40%, and the y-axis shows cumulative frequency percentage from 0 to 100. Two curves depict weight change distributions for the WEGOVY and placebo treatments.*

FDA Label Image

Fig 6 (Image 07)

This image shows two line graphs illustrating the percentage change in body weight over time (weeks and days) comparing WEGOVY and placebo groups. The Y-axis shows change in body weight percentage, and the X-axes show weeks and days. WEGOVY groups demonstrate greater weight reduction compared to placebo groups over the study periods.*

FDA Label Image

Fig 7 (Image 08)

Two line graphs comparing the percentage change in body weight over time for WEGOVY (semaglutide) versus placebo groups. The graphs show a significant reduction in body weight with WEGOVY compared to placebo across different time points, with data points and trend lines depicted for both groups on each graph.*

FDA Label Image

Strength (Image 09)

Wegovy packaging label showing multiple dosage strengths of semaglutide in injectable form. Visible strength options include 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL. Each strength is displayed in a distinct rectangular color block. The label is produced by Novo Nordisk Pharmaceutical Industries, LP.*

FDA Label Image

Ifu 1 (Image 10)

Illustration showing a WEGOVY (semaglutide) injection pen with labeled instruction to 'Pull out to get started.' Below the pen image is a diagram depicting a sectioned component, likely indicating how to prepare or activate the pen prior to use.*

FDA Label Image

Ifu 2 (Image 11)

Diagram illustrating WEGOVY pen parts before and after use. It highlights the expiration date location, dosage strength indicators, pen window showing medication clarity, needle cover status before and after use, and pen cap removal instructions. The illustration emphasizes verifying the medication has not expired, that the pen contains clear, colorless solution without air bubbles, and that the yellow bar in the pen window stops moving to confirm dose delivery.*

FDA Label Image

Ifu 3 (Image 12)

An anatomical diagram showing recommended injection sites on the human body for WEGOVY (semaglutide). The labeled areas include the upper arms, stomach, and upper legs, indicating where subcutaneous injections may be administered.*

FDA Label Image

Click Image (Image 13)

Instructional diagram showing a step-by-step guide on how to use an injection pen. Step 1: Click to start the injection. Step 2: Keep holding until the yellow bar stops moving. Final step: When the yellow bar stops, the injection is complete and the pen should be lifted slowly. The injection time is indicated to take about 5-10 seconds.*

FDA Label Image

Sharp Container (Image 14)

Illustration showing a hand holding a pen-like injector device that is being activated or prepared by pressing a button or cap, indicated by a downward arrow. The device is positioned above a biohazard sharps disposal container, demonstrating the proper disposal of the injector after use.*

FDA Label Image

Caution (Image 15)

FDA Label Image

Contact (Image 16)

FDA Label Image

0.25 mg (Image 17)

WEGOVY 0.25 mg/0.5 mL injection by Novo Nordisk Pharmaceutical Industries, LP, presented as a single-dose prefilled pen for subcutaneous use. The carton provides dosage instructions to use WEGOVY once a week and contains four single-dose prefilled pens, each delivering 0.25 mg semaglutide. The packaging includes the product name, strength, route, usage instructions, and a support website (startwegovy.com).*

FDA Label Image

0.5 mg (Image 18)

Packaging label for WEGOVY 0.5 mg (semaglutide) injection 0.5 mg/0.5 mL by Novo Nordisk Pharmaceutical Industries. The label shows a box containing 4 single-dose prefilled pens for subcutaneous use only, with instructions to use WEGOVY once a week. The image includes dosage information, product illustrations, and the Novo Nordisk logo.*

FDA Label Image

1 mg (Image 19)

WEGOVY 1 mg semaglutide injection in single-dose prefilled pens. The package includes 4 prefilled pens, each delivering 1 mg/0.5 mL for subcutaneous use. The label indicates use once a week and is manufactured by Novo Nordisk Pharmaceutical Industries, LP. The design features a white and brown color scheme with product and dosing information.*

FDA Label Image

1.7 mg (Image 20)

WEGOVY 1.7 mg (semaglutide) injection carton with 4 single-dose prefilled pens. The label shows dosage strength 1.7 mg per 0.75 mL, with instructions to use once weekly for subcutaneous injection. The manufacturer is Novo Nordisk Pharmaceutical Industries, LP. The packaging includes a blue and white color scheme with product and usage information.*

FDA Label Image

2.4 mg (Image 21)

WEGOVY 2.4 mg (semaglutide) injection 2.4 mg/0.75 mL single-dose prefilled pens by Novo Nordisk Pharmaceutical Industries, LP. The carton contains 4 single-dose prefilled pens for subcutaneous use and instructs use of WEGOVY once a week. The packaging prominently shows the product name, dosage strength, and pen illustration, with usage instructions and support website startwegovy.com.*

FDA Label Image

Step 3 (Image 22)

An instructional illustration showing a hand holding a WEGOVY (semaglutide) injection pen and another hand removing the pen cap, with labels indicating the location of the needle inside the cap. The image demonstrates proper removal of the pen cap prior to use.*

FDA Label Image

Step 4 (Image 23)

An instructional illustration showing a hand holding a WEGOVY (semaglutide) injection pen. The image demonstrates pushing the pen downwards, indicated by a downward arrow, likely depicting the step to administer the injection.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.